Sermorelin stimulates the pituitary to produce HGH 2 , while HGH therapy directly injects synthetic HGH
EBioMedicine (2020) 58:102913
Reported Research Benefits Selective GHS-R1a agonism without ACTH, cortisol, or prolactin elevation confirmed in human pharmacology studies Pulsatile GH release: preserves natural GH secretion rhythm (unlike continuous exogenous HGH) Stacked with CJC-1295 DAC: Teichman 2006 showed 210 GH elevation sustained for 911 days Improved body composition: lean mass gain, fat mass reduction in GH secretagogue literature Sleep quality improvement: GH secretion peaks during slow-wave sleep, enhanced by ipamorelin protocols Shorter half-life (~2 hours) allows dosing flexibility and rapid clearance vs long-acting alternatives Dosing Protocol & Reconstitution Reported Research Dosing Not Clinical Recommendations Ipamorelin is most commonly dosed alongside CJC-1295 because the two peptides hit independent receptors (ghrelin and GHRH) and their GH-releasing effects add together

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a 29-amino-acid peptide modified with a Drug Affinity Complex (DAC) that extends its biological half-life from minutes to several days
[PMID: 8585426] PubMed record related to this compound for laboratory literature review
This made chemotherapeutic medicine less harmful, increased peoples lifespans, and made it easier for better health care systems to develop